ASCO
Refine search
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Biotechnology
In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001. We interviewed president and chief executive Stacy Lindborg on the long path to this moment—and what may lie ahead in the evolving ovarian cancer treatment landscape. 28 May 2025
Pharmaceutical
Germany’s Merck KGaA today announced the presentation of detailed positive results from Part 1 of the global Phase III MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics, in the treatment of patients with tenosynovial giant cell tumor (TGCT). 28 May 2025
Biotechnology
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. 27 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Biotechnology
Swiss pharma major Roche has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Biotechnology
New data in bladder cancer could help make Bavencio (avelumab) more than just an also ran in checkpoint inhibition. 29 May 2020
Pharmaceutical
Swiss pharma major Novartis has announced a new exploratory subgroup analysis from the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20 Virtual Scientific Program. 27 May 2020
Pharmaceutical
At this year’s ASCO, positive Phase III data for Erleada (apalutamide) in prostate cancer will boost prescriber confidence in the therapy, building on datasets presented at last year’s event. 14 May 2020
Biotechnology
Ahead of featuring the data at the American Society of Clinical Oncology (ASCO) meeting later this month, results from the Phase III CheckMate-9LA trial, which demonstrated a statistically-significant and clinically-meaningful survival benefit with Opdivo (nivolumab) plus Yervoy (ipilimumab), given concomitantly with two cycles of chemotherapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC), have been released. 14 May 2020
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
Biotechnology
The headline-grabbing results on AMG 510, the first KRASG12C inhibitor to reach the clinical stage, were not the only data to be shared by US biotech Amgen on its early-stage oncology pipeline. 5 June 2019
Biotechnology
AbbVie has presented data from the CLL14 trial, examining Venclexta (venetoclax) plus Roche’s CD20 blocker Gazyva (obinutuzumab), as a first-line therapy for chronic lymphocytic leukaemia (CLL). 5 June 2019
Pharmaceutical
Swiss pharma giant Novartis has presented results from the COMBI-d and COMBI-v trials, testing a combination of Tafinlar (dabrafenib) and Mekinist (trametinib), at the 2019 ASCO annual meeting. 5 June 2019
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca and US drug giant Merck & Co have presented further evidence in support of Lynparza (olaparib) at the 2019 ASCO meeting. 4 June 2019
Biotechnology
Bristol-Myers Squibb has announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) at the annual meeting of the American Society of Clinical Oncology (ASCO). 4 June 2019
Biotechnology
Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen is definitely a contender at this year's event. 3 June 2019
Pharmaceutical
Japan’s Takeda Pharmaceutical has presented new data for TAK-788 during an oral session at the 2019 American Society of Clinical Oncology (ASCO) annual meeting. 3 June 2019
Pharmaceutical
An interim analysis of the Phase III ENZAMET trial has found that 80% of men with metastatic hormone-sensitive prostate cancer who received Xtandi (enzalutamide) along with standard-of-care treatment were alive at three years. 3 June 2019
Biotechnology
Merck & Co’s industry-leading immuno-oncology drug Keytruda (pembrolizumab) is no stranger to making the headlines at ASCO, and this year’s meeting is no exception. 3 June 2019
Pharmaceutical
Swiss pharma giant Novartis has released data showing statistically-significant overall survival (OS) results for the CDK4/6 inhibitor Kisqali (ribociclib), in combination with endocrine therapy. 3 June 2019
Biotechnology
Much awaited Phase III POLO trial data were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, and showed that Lynparza (olaparib) has a significant impact of progression of disease in certain pancreatic cancer patients. 3 June 2019
Biotechnology
Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s isatuximab in a looming head-to-head with Johnson & Johnson’s Darzalex (daratumumab). 3 June 2019
Biotechnology
Immunotherapy specialist Atara Biotherapeutics has presented clinical results relating to its biomarker research at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2019
Biotechnology
New baseline biomarker analyses and updated clinical study efficacy and safety results were shared in a presentation, titled "Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214, bempeg), at the 2019 American Society of Clinical Oncology (ASCO) meeting in Chicago. 3 June 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze